Weekly and seasonal changes of intraocular pressure measured with an implanted intraocular telemetry sensor

2020 ◽  
pp. bjophthalmol-2020-315970
Author(s):  
Kaweh Mansouri ◽  
Kevin Gillmann ◽  
Harsha Laxmana Rao ◽  
Robert N Weinreb
Keyword(s):  
Intraocular Pressure ◽  
Primary Open Angle Glaucoma ◽  
Open Angle Glaucoma ◽  
Seasonal Pattern ◽  
Statistical Significance ◽  
Open Label ◽  
Variation Patterns ◽  
Telemetric System ◽  
Multiple Comparison Correction

Background/AimsTo better understand seasonal and weekday intraocular pressure (IOP) variations, long-term daily IOP measurements were assessed in patients with glaucoma using an intraocular telemetric sensor.MethodsThis prospective, open-label, multicentre observational study analysed the IOP variation patterns in 22 eyes of 22 patients with primary open-angle glaucoma (67.8±6.8 years, 36.4% female) who had undergone placement of an intraocular telemetric sensor at the time of cataract surgery. The telemetric system combines an implantable IOP sensor with a hand-held reading device. Patients were instructed to self-measure their IOP as often as desired, but at least four times daily. Analysis of variance and Tukey multiple-comparison correction were used to assess the statistical significance of average and peak IOP variations between individual weekdays and months.ResultsEach enrolled patient recorded daily IOP measurements for an average duration of 721 days. On average, IOPs were highest on Wednesdays and lowest on Fridays (p=0.002). There were significant variations of IOP throughout the year, and IOP showed a seasonal pattern. Between mid-winter (December–January) and mid-summer months, there was a reduction in mean IOP of 8.1% (-1.55 mm Hg, p<0.05).ConclusionThis study confirms previously observed seasonal variations of IOP. IOP was significantly higher in winter compared with summer months. Moreover, IOP was lower on Friday than on other days. The explanation for these results is not known.

scholarly journals Influence of BAK-Preserved Prostaglandin Analog Treatment on the Ocular Surface Health in Patients with Newly Diagnosed Primary Open-Angle Glaucoma

2013 ◽  
Vol 2013 ◽  
pp. 1-7 ◽  
Author(s):  
Martina Tomić ◽  
Snježana Kaštelan ◽  
Kata Metež Soldo ◽  
Jasminka Salopek-Rabatić
Keyword(s):  
Intraocular Pressure ◽  
Ocular Surface ◽  
Primary Open Angle Glaucoma ◽  
Open Angle Glaucoma ◽  
Final Visit ◽  
Open Angle ◽  
Newly Diagnosed ◽  
Prostaglandin Analog ◽  
Ocular Surface Health

Purpose. Primary open-angle glaucoma (POAG), a chronic, degenerative optic neuropathy, requires persistent decrease of intraocular pressure so as to prevent visual impairment and blindness. However, long-term use of topical ocular medications may affect ocular surface health. Purpose of this study was to evaluate the influence of BAK-preserved prostaglandin analog treatment on the ocular surface health in patients with newly diagnosed POAG.Methods. 40 newly diagnosed POAG patients were included in this prospective study. Intraocular pressure (IOP), tear break-up time (TBUT), and ocular surface disease index (OSDI) were assessed at baseline and 3-month after starting treatment with BAK-preserved travoprost 0.004%.Results. IOP decreased in all patients from baseline to 3-month final visit (23.80 ± 1.73 mmHg versus 16.78 ± 1.27 mmHg;P<0.001). Mean TBUT decreased from11.70±1.86seconds at baseline to 8.30 ± 1.29 seconds at 3-month final visit (<0.001). Mean OSDI score increased from 31.63 ± 18.48 to 44.41 ± 16.48 (P<0.001).Conclusions. This study showed that BAK-preserved travoprost 0.004% is an effective medication in newly diagnosed POAG patients, but its long-term use may negatively influence ocular surface health by disrupting the tear film stability. Further studies are needed to better understand the clinical effects of different preservative types and concentrations on the ocular surface.

Long-Term Benefit of Reduced Intraocular Pressure in Primary Open-Angle Glaucoma Patients in Ethiopia

2010 ◽  
Vol 20 (2) ◽  
pp. 310-315 ◽  
Author(s):  
Abiye M. Alemu ◽  
Caroline J. Kristoffersen ◽  
Michael S. Kristoffersen ◽  
Jeanette A. Stewart ◽  
William C. Stewart
Keyword(s):  
Intraocular Pressure ◽  
Primary Open Angle Glaucoma ◽  
Open Angle Glaucoma ◽  
Open Angle ◽  
Term Benefit

scholarly journals Epidemiological Properties of Primary Open Angle Glaucoma in Nigeria

2013 ◽  
Vol 2013 ◽  
pp. 1-6 ◽  
Author(s):  
Lawan Abdu
Keyword(s):  
Intraocular Pressure ◽  
Primary Open Angle Glaucoma ◽  
Open Angle Glaucoma ◽  
High Reliability ◽  
Treatment Options ◽  
Late Presentation ◽  
Open Angle ◽  
Long Term Effects ◽  
Eye Care

Background. Primary open angle glaucoma (POAG) is progressive chronic optic neuropathy in adults in which intraocular pressure (IOP) and other currently unknown factors contribute to damage. POAG is the second commonest cause of avoidable blindness in Nigeria.Pattern of Presentation. POAG is characterized by late presentation. Absence of pain which is a driving force for seeking medical help, inadequacy of trained eye care personnel, paucity of facilities, misdistribution of resources, lack of awareness, poor education, and poverty may all contribute to this. Medical and surgical treatment options available are challenging and tasking.Screening for Glaucoma. Screening is the presumptive identification of unrecognized disease (POAG) by applying test(s) which can be applied rapidly. Such test(s) should be of high reliability, validity, yield, acceptable, and cost effective. The test should ideally be sensitive, specific, and efficient. It is difficult to select a suitable test that meets these criteria. Intraocular pressure (IOP) appears to be the easiest option. But, high IOP is not diagnostic nor does normal value exclude the disease. Health education is a possible strategy in early case detection and management.Treatment of POAG. Glaucoma treatment can either be medical or surgical (this includes laser). Considering unavailability, potency, cost, and long-term effects of medication, surgery (trabeculectomy) could be a better option. Laser trabeculoplasty is available in a few centers. Viscocanalostomy is not routinely performed. Patient education is vital to success as management is for life.Conclusion. POAG remains a cause of avoidable blindness in Nigeria. There is need for long-term strategy to identify patients early and institute prompt management. Improvement in training of eye care personnel and provision of up to date equipment is essential in achieving this goal.

scholarly journals Subconjunctival Bevacizumab as an Adjunct to 5-Fluorouracil Enhanced Trabeculectomy: 1 Year Outcomes

2021 ◽  
Vol 37 (3) ◽  
Author(s):  
Sana Nadeem
Keyword(s):  
Intraocular Pressure ◽  
Primary Open Angle Glaucoma ◽  
Open Angle Glaucoma ◽  
Exclusion Criteria ◽  
Quasi Experimental ◽  
Added Benefit ◽  
Bleb Formation ◽  
The Mean

Purpose:  To compare the results of trabeculectomy with subconjunctival Bevacizumab and 5-Fluorouracil (5-FU); with trabeculectomy with 5-FU alone; in terms of intraocular pressure (IOP) lowering, bleb formation, and complications, in the long term. Study Design:  Quasi experimental study. Place and Duration of Study:  Fauji Foundation Hospital, Rawalpindi, from December 2013 to August, 2019. Methods:  A total of 30 eyes (15 in each group) with glaucoma were recruited. Exclusion criteria were previous trabeculectomy, congenital, traumatic, uveitic, neovascular glaucomas, aphakia, or ocular surface disease. Trabeculectomy with 5FU was performed in both groups. In one group, subconjunctival Bevacizumab was injected into the bleb at the end of surgery. The patients were observed for IOP control, bleb configuration, and complications for 1 year. Results:  Primary open angle glaucoma was the predominant diagnosis in 17 (56.7%) eyes. The mean pre-operative IOP in the 5-FU group was 30.8 ± 17.03 mmHg, & in the 5-FU+Bevacizumab group it was 28.9 ± 18.9 mmHg. The mean IOPs of the 5-FU group at 1 Year was 14.5 ± 5.04 mmHg. In 5-FU+Bevacizumab group, mean IOPs at 1 year was 12.7 ± 4.38 mmHg. The differences between pre-operative and post-operative IOPs in both groups at 6, 9 and 12 months were statistically significant. However, differences in mean IOPs between the two groups, bleb morphology and complications were not statistically significant. Conclusion:  No added benefit of subconjunctival Bevacizumab used as an adjunct to 5-FU enhanced trabeculectomy was found at the end of 1 year follow-up. Key Words:  Trabeculectomy, 5-Fluorouracil, Bevacizumab, Glaucoma, Intraocular pressure.

scholarly journals Long term effect of phacoemulsification on intraocular pressure in patients with medically controlled primary open-angle glaucoma

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Loic Majstruk ◽  
Benjamin Leray ◽  
Aymeric Bouillot ◽  
Sylvain Michée ◽  
Gilles Sultan ◽  
...  
Keyword(s):  
Intraocular Pressure ◽  
Primary Open Angle Glaucoma ◽  
Open Angle Glaucoma ◽  
Term Effect ◽  
Open Angle ◽  
Long Term Effect

scholarly journals Effect of benzalkonium chloride-preserved latanoprost and benzalkonium chloride-free latanoprost on intraocular pressure in patients of primary open angle glaucoma

2018 ◽  
Vol 6 (7) ◽  
pp. 2495
Author(s):  
Anjleen Kaur ◽  
Shikha Palta ◽  
Hema Chhabra ◽  
Gursatinder Singh ◽  
Anita Gupta
Keyword(s):  
Intraocular Pressure ◽  
Benzalkonium Chloride ◽  
Primary Open Angle Glaucoma ◽  
Open Angle Glaucoma ◽  
Switch Trial ◽  
P Value ◽  
Open Angle ◽  
Open Label ◽  
Lowering Effect ◽  
Change In Mean

Background: To evaluate the change in mean IOP with BKC-preserved latanoprost versus BKC-free latanoprost in patients of primary open angle glaucoma (POAG).Methods: This was an open-label, randomized, interventional, switch trial. Thirty patients of primary open angle glaucoma (POAG) who were already on benzalkonium chloride (BKC)-preserved latanoprost for a minimum of three months were recruited. Their intraocular pressure (IOP) was recorded at the baseline. Then, they were switched over to benzalkonium chloride (BKC)-free latanoprost for another three months. Their intraocular pressure (IOP) was recorded at both 6 and 12 weeks of follow-up.Results: IOP decreased from 15.57±0.85mm Hg at baseline to 15.40±0.89mm Hg at 6 weeks to 15.30±0.70mm Hg at 12 weeks. p value was found to be 0.209 and 0.115 at 6 and 12 weeks respectively. No statistically significant change was observed between mean IOP at both 6 and 12 weeks as compared to the baseline.Conclusions: BKC-free medications have equal IOP lowering effect as BKC-preserved medications in glaucoma patients.

Sign in / Sign up

Export Citation Format

Share Document